JP2011518833A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518833A5
JP2011518833A5 JP2011506415A JP2011506415A JP2011518833A5 JP 2011518833 A5 JP2011518833 A5 JP 2011518833A5 JP 2011506415 A JP2011506415 A JP 2011506415A JP 2011506415 A JP2011506415 A JP 2011506415A JP 2011518833 A5 JP2011518833 A5 JP 2011518833A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutically acceptable
acceptable salt
following formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011506415A
Other languages
English (en)
Other versions
JP2011518833A (ja
JP5524181B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/041389 external-priority patent/WO2009132088A1/en
Publication of JP2011518833A publication Critical patent/JP2011518833A/ja
Publication of JP2011518833A5 publication Critical patent/JP2011518833A5/ja
Application granted granted Critical
Publication of JP5524181B2 publication Critical patent/JP5524181B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 下記構造より選ばれる式の化合物
    Figure 2011518833
    Figure 2011518833
    (式中、Yは、以下の基
    Figure 2011518833
    である)。
  2. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  3. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  4. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  5. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  6. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  7. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  8. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  9. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  10. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  11. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  12. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  13. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  14. 下記式の請求項1に記載の化合物、又はその医薬的に許容され得る塩。
    Figure 2011518833
  15. 脱毛症の治療用組成物を製造するための、請求項1〜14のいずれか一項に記載の化合物の使用
JP2011506415A 2008-04-24 2009-04-22 治療剤としての置換ガンマラクタム Expired - Fee Related JP5524181B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4750108P 2008-04-24 2008-04-24
US61/047,501 2008-04-24
PCT/US2009/041389 WO2009132088A1 (en) 2008-04-24 2009-04-22 Substituted gamma lactams as therapeutic agents

Publications (3)

Publication Number Publication Date
JP2011518833A JP2011518833A (ja) 2011-06-30
JP2011518833A5 true JP2011518833A5 (ja) 2012-06-14
JP5524181B2 JP5524181B2 (ja) 2014-06-18

Family

ID=40852537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506415A Expired - Fee Related JP5524181B2 (ja) 2008-04-24 2009-04-22 治療剤としての置換ガンマラクタム

Country Status (19)

Country Link
US (1) US7820661B2 (ja)
EP (1) EP2291368B1 (ja)
JP (1) JP5524181B2 (ja)
KR (1) KR20110008263A (ja)
CN (1) CN102076681A (ja)
AU (1) AU2009239372B2 (ja)
BR (1) BRPI0911347A2 (ja)
CA (1) CA2722529A1 (ja)
CO (1) CO6321273A2 (ja)
DK (1) DK2291368T3 (ja)
ES (1) ES2399314T3 (ja)
IL (1) IL208899A0 (ja)
MX (1) MX2010011636A (ja)
MY (1) MY150518A (ja)
PL (1) PL2291368T3 (ja)
RU (1) RU2543379C2 (ja)
UA (1) UA103616C2 (ja)
WO (1) WO2009132088A1 (ja)
ZA (1) ZA201007553B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
EP2113246B1 (en) 2003-08-07 2016-06-22 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP2288385A2 (en) * 2008-04-16 2011-03-02 Allergan, Inc. Combination therapy for glaucoma
EP2291367A1 (en) * 2008-04-24 2011-03-09 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2009142969A1 (en) * 2008-05-20 2009-11-26 Allergan, Inc. Therapeutic lactams
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20120322882A1 (en) 2009-11-09 2012-12-20 Allergan, Inc. Compositions And Methods For Stimulating Hair Growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CA2882138C (en) * 2012-08-21 2020-10-27 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CA2962766A1 (en) * 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US395798A (en) * 1889-01-08 reason
US4007210A (en) 1973-04-27 1977-02-08 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenylmethoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanates
US3985798A (en) 1975-01-27 1976-10-12 American Cyanamid Company 11α-HOMO-PROSTANOIC ACIDS AND ESTERS
US4060540A (en) 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
ES2052735T3 (es) 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US6034413A (en) * 1997-02-27 2000-03-07 Texas Instruments Incorporated High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AU2002328855B2 (en) * 2001-07-16 2005-11-24 F. Hoffmann-La Roche Ag Prostaglandin Analogues As EP4 Receptor Agonists
ATE305463T1 (de) 2001-11-05 2005-10-15 Allergan Inc Omega-zykloalkyl 17-heteroaryl prostaglandin-e2- analoga als ep2-rezeptoragonisten
NZ535024A (en) * 2002-03-05 2006-10-27 Ono Pharmaceutical Co 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2003237520B2 (en) 2002-06-10 2009-01-08 Laboratoires Serono Sa Gamma lactams as prostaglandin agonists and use thereof
AU2003275838A1 (en) 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
DE602005014671D1 (de) * 2004-12-22 2009-07-09 Janssen Pharmaceutica Nv Tricyclische delta-opioid-modulatoren
DK1856042T3 (da) 2005-03-10 2012-09-17 Allergan Inc Substituerede gamma-lactamer som terapeutiske midler
US8039507B2 (en) 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
US7592364B2 (en) 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2007226957B2 (en) 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
US7482475B2 (en) 2006-08-11 2009-01-27 Allergan, Inc. Therapeutic lactams
US7507817B2 (en) 2006-11-17 2009-03-24 Allergan, Inc. Prostaglandin prodrugs
BRPI0808377B8 (pt) * 2007-01-31 2021-05-25 Allergan Inc composto, composição e uso de um composto
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
EP2291367A1 (en) * 2008-04-24 2011-03-09 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Similar Documents

Publication Publication Date Title
JP2011518833A5 (ja)
JP2009149903A5 (ja)
JP2009535462A5 (ja)
JP2011105738A5 (ja)
JP2013032389A5 (ja)
JP2010501534A5 (ja)
JP2013532130A5 (ja)
JP2010536766A5 (ja)
JP2011510079A5 (ja)
JP2019194236A5 (ja)
JP2007269812A5 (ja)
JP2011527560A5 (ja)
JP2012107057A5 (ja)
JP2014500861A5 (ja)
JP2007522220A5 (ja)
JP2012111758A5 (ja)
JP2012144574A5 (ja)
JP2013508347A5 (ja)
JP2010529196A5 (ja)
JP2010530897A5 (ja)
JP2006526031A5 (ja)
JP2013507423A5 (ja)
JP2008513510A5 (ja)
JP2017514910A5 (ja)
JP2011519871A5 (ja)